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Background: Patients with common at-risk genetic variants have increased MACE following percutaneous coronary intervention (PCI). Ultra rapid 
genotyping may facilitate a pharmacogenomic approach to anti-platelet therapy in STEMI patients receiving PCI.
method: We utilized a point-of-care genetic device, designed to identify CYP2C19*2, ABCB1 3435 C→T and CYP2C19*17 carriers, to evaluate 
the potential of a pharmacogenomic strategy in STEMI patients. Following successful PCI, CYP2C19*2 carriers and ABCB1 3435 TT homozygotes 
were randomized to a strategy of prasugrel 10mg daily for 1 month or clopidogrel 150mg daily for 7 days then 75mg daily for 3 weeks. The primary 
endpoint is the proportion of CYP2C19*2 and/or ABCB1 3435 TT carriers with high on-treatment platelet reactivity (HPR) (defined by P2Y12 
reactivity unit (PRU) >234) in the prasugrel compared to the clopidogrel arm at 1 month. 
results: Among 102 patients, 59 (57.8%) were randomized following identification of at least one at-risk genotype. Overall, 36.3% and 32.3% were 
CYP2C19*2 and ABCB1 3435 TT carriers, respectively. The baseline PRU was 183.5±90.6 among carriers compared with 147.3±84.7 in non-carriers, 
p=0.04. Primary and secondary outcomes are shown below: 
Primary and Secondary Platelet Function Outcomes According to Assigned Groups
Patients without at-risk 
genetic variants
(N=43)
At-risk patients randomized to 
Prasugrel
(N=30)
At-risk patients randomized to 
High-dose Clopidogrel
(N=29)
p-value†
Primary Outcome
Patients with PRU>234 at 
Day 30 - no.(%)
2(4.7) 0(0) 7(24.1) 0.005
Patients with PRU>208 at 
Day 30 - no.(%)
4(9.3) 1(3.3) 10(34.5) 0.003
Secondary Outcomes
Baseline PRU 147.3±84.7 192.6±100.5 174.1±80.6 0.440
PRU at Day 30 110.4±85.1 53.8±60.3 157.1±94.7 <0.001
% Platelet Inhibition at 
Day 30
59.6±28.5 80.0±21.6 42.3±31.9 <0.001
Plus-minus values are mean ±SD, PRU = P2Y12 Reactivity Unit
† - p-values between patients randomized to prasugrel vs. high-dose clopidogrel
conclusions: Point-of-care genetic testing permitted rapid identification of STEMI patients with an increased propensity for HPR. Alteration to 
prasugrel in carriers of at-risk genetic variants decreased HPR compared to a strategy of high-dose clopidogrel.
